DNA topoisomerase-targeting antitumor agents and drug resistance.
A review of the chemotherapeutic agents which have been developed by targeting DNA topoisomerase I and II is presented. Camptothecins as topoisomerase I-targeting agents and newly developed topoisomerase II-targeting agents with unique properties are expected to be promising anticancer agents in the near future. An important issue is how cellular sensitivity to these agents is controlled. One approach is to establish and characterize drug-resistant human cancer cell lines, which would provide powerful tools to understand their intracellular target sites and also the mechanisms for acquirement of drug resistance to topoisomerase inhibitors. Drug resistance to topoisomerase-targeting agents appears to be closely correlated with two events, namely decreased expression and point mutation of topoisomerase genes.
Takano
H
H
Department of Biochemistry, Oita Medical University, Japan.
Kohno
K
K
Matsuo
K
K
Matsuda
T
T
Kuwano
M
M
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002166:Camptothecin / Q000494:pharmacology; D004264:DNA Topoisomerases, Type I / Q000187:drug effects*; D004351:Drug Resistance / Q000502:physiology; D005047:Etoposide / Q000494:pharmacology; D006801:Humans; D013713:Teniposide / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D005047:Etoposide; D013713:Teniposide; D004264:DNA Topoisomerases, Type I; D002166:Camptothecin